Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 249-256

  O'Dwyer, P J ^a   Hamilton, T C ^a   LaCreta, F P ^a   Gallo, J M ^a   Kilpatrick, D ^a   Halbherr, T ^a   Brennan, J ^a   Bookman, M A ^a   Hoffman, J ^a   Young, R C ^a   Comis, R L ^a   Ozols, R F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTATHIONE; MELPHALAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SENSITIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 9044254931     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.249     Document Type: Article

References (27)

1. Meister A, Anderson ME: Glutathione. Annu Rev Biochem 52:711-760, 1983
2. Suzukake K, Petro BJ, Vistica DT: Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 32:165-167, 1983
3. Begleiter A, Grover J, Froese E: Membrane transport, sulfhydryl levels and DNA cross-linking in Chinese hamster ovary cell mutants sensitive and resistance to melphalan. Biochem Pharmacol 32:293-300, 1983
4. Somfai-Relle S, Suzukake K, Vistica BP: Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem Pharmacol 33:485-490, 1984
5. Hamilton TC, Winker MA, Louie KG, et al: Augmentation of Adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:2583-2586, 1985
6. Ozols RF, Louie KG, Plowman J, et al: Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 36:147-153, 1987
7. Godwin AK, Meister A, O'Dwyer PJ, et al: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89:3070-3074, 1992
8. Griffith OW, Meister A: Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254:7558-7560, 1979
9. Griffith OW: Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologues, potent inhibitors of glutathione synthesis. J Biol Chem 257:13704-13712, 1982
10. Kramer RA, Greene K, Ahmad S, et al: Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res 47:1593-1597, 1987
11. Smith AC, Liao JT, Page JG, et al: Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Cancer Res 49:5385-5391, 1989
12. Louie KG, Behrens BS, Kinsella TJ, et al: Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45:2110-2115, 1985
13. O'Dwyer PJ, Hamilton TC, Young RC, et al: Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical results. J Natl Cancer Inst 84:264-267, 1992
14. LaCreta FP, Brennan J, Hamilton TC, et al: Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. Drug Metab Dispos 22:835-842, 1994
15. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. Griffith OW: Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106:207-212, 1980
17. Brennan J, O'Dwyer PJ, Ozols RF, et al: High-performance liquid chromatographic determination of the (S)- and (R)-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine. J Chromatogr 620:121-128, 1993
18. Rocci ML, Jasko WI: LAGRAN program for area and moments in pharmacokinetic analysis. Comp Prog Biored 16:203-216, 1983
19. S-plus, version 3.1. Seattle, WA, Statistical Sciences, Inc, 1991
20. Doshi KJ, Gallo JM, Boudinot FD, et al: Comparative pharmacokinetics of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZddU) in mice. Drug Metab Dispos 17:590-594, 1989
21. Britten RA, Green JA, Warenius HM: Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 24:527-531, 1992
22. Bolton MG, Hilton J, Robertson KD, et al: Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. Drug Metab Dispos 21:986-996, 1993
23. Colvin OM, Friedman HS, Gamcsik MP, et al: Role of glutatione in cellular resistance to alkylating agents. Adv Enzyme Regul 33:19-26, 1993
24. Schröder CP, Godwin AK, O'Dwyer PJ, et al: Glutathione and drug resistance. Cancer Invest (in press)
25. Meister A: A selective modification of glutathione metabolism. Science 220:472-477, 1983
26. Bailey HH, Mulcahy RT, Tutsch KD, et al: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. J Clin Oncol 12:194-205, 1994
27. Yao K-S, Godwin AK, Ozols RF, et al: Variable baseline γ-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res 53:3662-3666, 1993